THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study

BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these c...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 75; no. Suppl 2; p. 339
Main Authors Bautista-Molano, W., Landewé, R., Moltό, A., Burgos-Vargas, R., Maldonado-Cocco, J., Valle-Oñate, R., van der Heijde, D.
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group LTD 01.06.2016
Online AccessGet full text

Cover

Loading…
More Information
Summary:BackgroundIncreased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.ObjectivesTo determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased.MethodsData of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis.ResultsIn total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population.ConclusionsIn patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.ReferencesMolto A, et al. Ann Rheum Dis 2015 Oct 21 pii: annrheumdis-2015–208174Gherghe AM, et al. RMD Open 2015 Sept 14;1(1):e000128Hernández-Hernández R, J Hypertens 2010, 28:24–34Disclosure of InterestNone declared
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2016-eular.1814